Perrigo Company plc Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Sales
Perrigo Company plc (PRGO) reported Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Sales of $12.50 million for the 12-month period ending 2017-12-31, per its 10-K filed 2020-02-27.
Discontinued › Income Statement › Other Income
us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySales · last filed 2020-02-27
- Perrigo Company plc fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, sales for fiscal 2017 was $12.50M.
| Period end | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Sales 12 month |
|---|---|
| 2017-12-31 | $12.50M 10-K · filed 2020-02-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| Bausch Health Companies Inc. (BHC) | $2.113B | -1.68 | |
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |